H.C. Wainwright Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $24
Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
Needham Maintains Cidara Therapeutics(CDTX.US) With Buy Rating, Maintains Target Price $25
Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
Buy Rating Justified by Cidara Therapeutics' Upcoming Clinical Trials and Expanding Oncology Pipeline
Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
HC Wainwright & Co. Maintains Buy on Cidara Therapeutics, Maintains $6 Price Target
Buy Rating Affirmed for Cidara Therapeutics Amid Promising Oncology Program Developments
Analysts' Top Healthcare Picks: Cidara Therapeutics (CDTX), Enveric Biosciences (ENVB)
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Cidara Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Cidara Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioCryst (BCRX), Cidara Therapeutics (CDTX) and Carisma Therapeutics (CARM)
HC Wainwright & Co. Reiterates Buy on Cidara Therapeutics, Maintains $6 Price Target
Cidara Therapeutics Analyst Ratings
No Data
No Data